No Data
No Data
Broge Pharmaceuticals: 2024 Semi-Annual Report Summary
Broge Pharmaceuticals: Semi-Annual Report 2024
Boji Medical Technology (300404.SZ) has reached a strategic cooperation with Boao Jingfang in the field of innovative drugs for traditional Chinese medicine.
Boji Medical Technology (300404.SZ) announced that the company and its wholly-owned subsidiary Xinglin Traditional Chinese Medicine Technology (Guangzhou) Limited...
Boji Medical Technology (300404.SZ) released its performance for the first half of the year, with a net income of 30.1351 million yuan, an increase of 71.04%.
Boji Medical Technology (300404.SZ) released its 2024 interim report, with a revenue of 0.341 billion...
boji medical technology (300404.SZ): net income in the first half of the year was 30.1351 million yuan, a year-on-year increase of 71.04%.
On August 26, Boji Medical Technology (300404.SZ) announced its semi-annual report for 2024, with revenue of 0.341 billion yuan, a year-on-year increase of 46.92%; net income attributable to shareholders of the listed company was 30.1351 million yuan, a year-on-year increase of 71.04%; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 25.6604 million yuan, a year-on-year increase of 164.08%; basic earnings per share was 0.0789 yuan.
Boji Medical Technology (300404.SZ): Currently, there are no clinical research projects for treating monkeypox with traditional Chinese medicine.
Boji Medical Technology (300404.SZ) stated on the investor interaction platform on August 19 that the company currently has no clinical research projects on traditional Chinese medicine for treating monkeypox.
No Data